News


( Last Updated : March 7, 2015)

June 30, 2022
CADTH is pleased to announce the release of a new report entitled Building Toward a Potential Pan-Canadian Formulary: A Report From the Advisory Panel. In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and managing a potential pan-Canadian…
June 27, 2022
CADTH is undertaking an innovative review for an antiviral treatment to address the recent monkeypox outbreaks. Monkeypox has become a serious public health issue around the globe. According to WHO, the most recent case fatality ratio from monkeypox infection is about 3% to 6%. The causes of death…
June 10, 2022
CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space…
June 1, 2022
June 1, 2022 – CADTH, the pan-Canadian health technology assessment body, will host a national roundtable on models of care for post–COVID-19 condition on June 1, 2022. Post–COVID-19 condition, or long COVID, is characterized by persistent or lingering symptoms that continue for weeks, months, or…
April 27, 2022
CADTH is expanding its Scientific Advice program to include applications for advice on real-world evidence (RWE) generation plans after protocols for pivotal trials have been finalized. This is an opportunity for pharmaceutical companies to enhance their engagement with CADTH regarding RWE. The…